Selective inhibition of NADPH-oxidase isoforms as a therapeutic strategy in hypertension

Hypertension is a major public health challenge because of its high frequency and associated cardiovascular risk. Accumulating evidence suggests that reactive oxygen species derived from NADPH-oxidase play a pivotal role in vascular damage associated with hypertension. The clinical benefits of three of the most prescribed classes of cardiovascular drugs might all indirectly involve inhibition of NADPH-oxidase. Thus, development of inhibitors of vascular isoforms of NADPH-oxidase could have substantial benefit in the treatment of hypertension